loading
前日終値:
$167.37
開ける:
$166.73
24時間の取引高:
539.56K
Relative Volume:
0.60
時価総額:
$8.32B
収益:
$4.02B
当期純損益:
$-79.62M
株価収益率:
-108.62
EPS:
-1.5551
ネットキャッシュフロー:
$543.67M
1週間 パフォーマンス:
-5.94%
1か月 パフォーマンス:
+1.77%
6か月 パフォーマンス:
+5.74%
1年 パフォーマンス:
+1.37%
1日の値動き範囲:
Value
$166.47
$170.16
1週間の範囲:
Value
$166.47
$182.65
52週間の値動き範囲:
Value
$91.86
$228.88

Charles River Laboratories International Inc Stock (CRL) Company Profile

Name
名前
Charles River Laboratories International Inc
Name
セクター
Healthcare (1109)
Name
電話
781-222-6000
Name
住所
251 BALLARDVALE ST, WILMINGTON, MA
Name
職員
19,700
Name
Twitter
@criverlabs
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
CRL's Discussions on Twitter

Compare CRL vs TMO, DHR, IDXX, A, WAT

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Diagnostics & Research icon
CRL
Charles River Laboratories International Inc
168.91 8.32B 4.02B -79.62M 543.67M -1.5551
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
495.72 184.15B 44.56B 6.72B 6.29B 17.74
Diagnostics & Research icon
DHR
Danaher Corp
195.06 137.93B 24.57B 3.60B 5.26B 5.051
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
600.52 47.82B 4.30B 1.06B 1.04B 13.08
Diagnostics & Research icon
A
Agilent Technologies Inc
115.42 32.62B 7.07B 1.29B 993.00M 4.5355
Diagnostics & Research icon
WAT
Waters Corp
297.54 29.19B 3.17B 642.63M 516.49M 10.77

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-12-15 アップグレード BofA Securities Neutral → Buy
2025-11-17 アップグレード Argus Hold → Buy
2025-11-06 アップグレード Robert W. Baird Neutral → Outperform
2025-10-06 アップグレード William Blair Mkt Perform → Outperform
2025-10-02 アップグレード Barclays Equal Weight → Overweight
2025-09-09 アップグレード Jefferies Hold → Buy
2025-07-09 アップグレード Citigroup Neutral → Buy
2025-05-23 アップグレード Redburn Atlantic Neutral → Buy
2025-05-14 アップグレード TD Cowen Hold → Buy
2025-05-08 アップグレード Evercore ISI In-line → Outperform
2025-03-21 ダウングレード Goldman Buy → Neutral
2025-03-04 アップグレード Citigroup Sell → Neutral
2025-03-03 アップグレード Redburn Atlantic Sell → Neutral
2025-01-22 ダウングレード William Blair Outperform → Mkt Perform
2025-01-17 ダウングレード UBS Buy → Neutral
2024-11-18 ダウングレード CLSA Hold → Underperform
2024-11-07 アップグレード CLSA Underperform → Hold
2024-10-23 開始されました CLSA Underperform
2024-10-14 開始されました Redburn Atlantic Sell
2024-10-07 ダウングレード Evercore ISI Outperform → In-line
2024-10-02 ダウングレード BofA Securities Buy → Neutral
2024-10-01 ダウングレード Citigroup Neutral → Sell
2024-08-08 ダウングレード JP Morgan Overweight → Neutral
2024-08-08 ダウングレード Robert W. Baird Outperform → Neutral
2024-06-28 ダウングレード Argus Buy → Hold
2024-06-07 開始されました Mizuho Neutral
2024-06-06 開始されました Goldman Buy
2024-02-15 ダウングレード Guggenheim Buy → Neutral
2023-09-13 開始されました TD Cowen Market Perform
2023-07-10 ダウングレード Citigroup Buy → Neutral
2023-02-23 アップグレード Guggenheim Neutral → Buy
2023-01-12 ダウングレード Jefferies Buy → Hold
2022-09-30 アップグレード Jefferies Hold → Buy
2022-08-25 開始されました Credit Suisse Outperform
2022-08-04 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-05-24 開始されました Guggenheim Neutral
2022-04-25 ダウングレード Jefferies Buy → Hold
2022-04-07 開始されました Stephens Overweight
2022-02-17 繰り返されました BofA Securities Buy
2022-02-17 アップグレード Citigroup Neutral → Buy
2022-02-17 繰り返されました Deutsche Bank Buy
2022-02-17 繰り返されました Morgan Stanley Overweight
2022-02-17 繰り返されました UBS Buy
2021-08-05 再開されました Credit Suisse Neutral
2020-12-16 ダウングレード Citigroup Buy → Neutral
2020-09-10 アップグレード Jefferies Hold → Buy
2020-07-01 アップグレード BofA Securities Neutral → Buy
2020-05-13 アップグレード UBS Neutral → Buy
2020-04-21 ダウングレード Jefferies Buy → Hold
2020-03-27 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-03-02 開始されました Deutsche Bank Buy
2020-02-18 アップグレード Wolfe Research Peer Perform → Outperform
2020-01-10 アップグレード Goldman Neutral → Buy
2020-01-08 開始されました Wells Fargo Overweight
2020-01-07 開始されました Citigroup Buy
2019-10-18 ダウングレード BofA/Merrill Buy → Neutral
2019-06-10 開始されました SVB Leerink Outperform
2019-04-30 再開されました Evercore ISI Outperform
2018-12-14 開始されました Deutsche Bank Buy
2018-10-09 開始されました UBS Neutral
2018-08-23 アップグレード Raymond James Mkt Perform → Outperform
2018-07-17 アップグレード RBC Capital Mkts Sector Perform → Outperform
2018-06-15 アップグレード KeyBanc Capital Mkts Sector Weight → Overweight
2018-02-14 アップグレード SunTrust Hold → Buy
すべてを表示

Charles River Laboratories International Inc (CRL) 最新ニュース

pulisher
05:55 AM

Natixis Advisors LLC Acquires 20,050 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat

05:55 AM
pulisher
03:24 AM

Barclays PLC Reduces Holdings in Charles River Laboratories International, Inc. $CRL - MarketBeat

03:24 AM
pulisher
Mar 11, 2026

Locus Cell, Taiwan-Based Cell and Gene Therapy CDMO, Signs MoU with Charles River at APAC Biomanufacturing Leadership Summit - PR Newswire

Mar 11, 2026
pulisher
Mar 10, 2026

Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Mar 10, 2026
pulisher
Mar 10, 2026

[Latest] Global Pharmaceutical Microbiology QC Testing Market Size/Share Worth USD 17.65 Billion by 2035 at a 13.27% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, SWOT Analysis) - GlobeNewswire Inc.

Mar 10, 2026
pulisher
Mar 10, 2026

CRL: Biotech demand is recovering, tech investments continue, and acquisitions strengthen core focus - TradingView

Mar 10, 2026
pulisher
Mar 10, 2026

CRL: Biotech demand rebounds, portfolio streamlined, and China’s innovation eyed for future growth - TradingView

Mar 10, 2026
pulisher
Mar 10, 2026

Charles River Laboratories International (CRL) Gains on Strong Results and Resilient Drug Outsourcing Demand - Yahoo Finance

Mar 10, 2026
pulisher
Mar 09, 2026

A Look At Charles River Laboratories (CRL) Valuation After 2026 Guidance Cut And Planned Divestitures - Yahoo Finance UK

Mar 09, 2026
pulisher
Mar 09, 2026

Dimensional Fund Advisors LP Purchases 120,207 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat

Mar 09, 2026
pulisher
Mar 09, 2026

A Look Back at Drug Development Inputs & Services Stocks' Q4 Earnings: Charles River Laboratories (NYSE:CRL) Vs The Rest Of The Pack - Finviz

Mar 09, 2026
pulisher
Mar 08, 2026

How Investors Are Reacting To Charles River Laboratories (CRL) Cutting 2026 Guidance After Planned Divestitures - Yahoo Finance

Mar 08, 2026
pulisher
Mar 07, 2026

GW&K Investment Management LLC Increases Position in Charles River Laboratories International, Inc. $CRL - MarketBeat

Mar 07, 2026
pulisher
Mar 07, 2026

Why Charles River Laboratories International Inc. stock is upgraded to buy2025 Sector Review & AI Enhanced Trading Alerts - Naître et grandir

Mar 07, 2026
pulisher
Mar 06, 2026

Quantbot Technologies LP Invests $1.44 Million in Charles River Laboratories International, Inc. $CRL - MarketBeat

Mar 06, 2026
pulisher
Mar 05, 2026

Charles River Laboratories International (CRL) Faces Biotech R&D Spending Headwinds - Insider Monkey

Mar 05, 2026
pulisher
Mar 05, 2026

Picton Mahoney Asset Management Boosts Stock Holdings in Charles River Laboratories International, Inc. $CRL - MarketBeat

Mar 05, 2026
pulisher
Mar 05, 2026

LaPlume buys Charles River Labs [CRL] shares worth $4363 - Investing.com India

Mar 05, 2026
pulisher
Mar 05, 2026

How Charles River Laboratories International Inc. (CRL) Affects Rotational Strategy Timing - Stock Traders Daily

Mar 05, 2026
pulisher
Mar 05, 2026

Risk Hedge: Is Charles River Laboratories International Inc a potential multi baggerTrade Exit Summary & Safe Capital Preservation Plans - baoquankhu1.vn

Mar 05, 2026
pulisher
Mar 04, 2026

Charles River Laboratories: Why Wall Street Suddenly Cares About This Quiet Biotech Powerhouse - AD HOC NEWS

Mar 04, 2026
pulisher
Mar 04, 2026

Insider Buying: Joseph Laplume Acquires Shares in Charles River Laboratories International Inc (CRL) - GuruFocus

Mar 04, 2026
pulisher
Mar 04, 2026

Charles River (NYSE: CRL) CEO receives 16,796-share stock-based award - Stock Titan

Mar 04, 2026
pulisher
Mar 04, 2026

Charles River (NYSE: CRL) EVP adds 25 shares in open-market buy - Stock Titan

Mar 04, 2026
pulisher
Mar 04, 2026

Charles River Laboratories: Is Wall Street Underpricing This Quiet Biotech Enabler? - AD HOC NEWS

Mar 04, 2026
pulisher
Mar 04, 2026

Charles River (CRL) Trims 2026 Outlook After Divestitures and Leadership Changes Is The Strategy Working? - simplywall.st

Mar 04, 2026
pulisher
Mar 04, 2026

Charles River Laboratories International, Inc. $CRL Shares Sold by Citigroup Inc. - MarketBeat

Mar 04, 2026
pulisher
Mar 03, 2026

Assessing Charles River Laboratories (CRL) Valuation After Recent Mixed Share Price Performance - simplywall.st

Mar 03, 2026
pulisher
Mar 03, 2026

Charles River expands footprint at Heriot-Watt University Research Park - Heriot-Watt University

Mar 03, 2026
pulisher
Mar 02, 2026

Charles River Laboratories to Present at TD Cowen and Barclays Conferences - Business Wire

Mar 02, 2026
pulisher
Mar 02, 2026

Charles River Laboratories (CRL) Stock Analysis: Navigating the Healthcare Research Sector with 10.48% Upside Potential - DirectorsTalk Interviews

Mar 02, 2026
pulisher
Feb 28, 2026

Charles River Laboratories Experiences Evaluation Revision Amidst Mixed Market Indicators - Markets Mojo

Feb 28, 2026
pulisher
Feb 28, 2026

Could Cash Machine Charles River Laboratories International Stock Be Your Next Buy? - Trefis

Feb 28, 2026
pulisher
Feb 27, 2026

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch

Feb 27, 2026
pulisher
Feb 27, 2026

Charles River Laboratories parts ways with its CDMO business - European Pharmaceutical Review

Feb 27, 2026
pulisher
Feb 27, 2026

Charles River Laboratories International, Inc. $CRL Stock Holdings Increased by JPMorgan Chase & Co. - MarketBeat

Feb 27, 2026
pulisher
Feb 27, 2026

Charles River Laboratories to divest a number of assets to IQVIA and GI Partners - Business Weekly

Feb 27, 2026
pulisher
Feb 26, 2026

IQVIA to acquire Charles River drug discovery assets - Yahoo Finance

Feb 26, 2026
pulisher
Feb 25, 2026

Charles River to sell CDMO and European discovery assets By Investing.com - Investing.com Australia

Feb 25, 2026
pulisher
Feb 25, 2026

Charles River Laboratories Experiences Revision in Its Stock Evaluation Amid Mixed Financial Indicators - Markets Mojo

Feb 25, 2026
pulisher
Feb 25, 2026

UBS Group Issues Positive Forecast for Charles River Laboratories International (NYSE:CRL) Stock Price - MarketBeat

Feb 25, 2026
pulisher
Feb 25, 2026

Activist investor prompts sale of Charles River CDMO business, U.S. and European sites - The Business Journals

Feb 25, 2026
pulisher
Feb 25, 2026

IQVIA Holdings Inc. (NYSE : IQV) entered into a definitive agreement to acquire European Discovery Services Assets from Charles River Laboratories International, Inc. (NYSE - marketscreener.com

Feb 25, 2026
pulisher
Feb 25, 2026

Charles River Laboratories (CRL) Announces Strategic Divestitures to Streamline Operations - GuruFocus

Feb 25, 2026
pulisher
Feb 25, 2026

UBS Adjusts Price Target on Charles River Laboratories International to $175 From $170, Maintains Neutral Rating - marketscreener.com

Feb 25, 2026
pulisher
Feb 25, 2026

Sector Update: Health Care - marketscreener.com

Feb 25, 2026
pulisher
Feb 25, 2026

Charles River Labs Breaks The Mold, Announces Bold Divestiture Plans - Benzinga

Feb 25, 2026
pulisher
Feb 25, 2026

Charles River announces divestitures, updates guidance - MSN

Feb 25, 2026
pulisher
Feb 25, 2026

Charles River to sell CDMO and European discovery assets - Investing.com

Feb 25, 2026
pulisher
Feb 25, 2026

Charles River Laboratories stock rises on divestiture plans By Investing.com - Investing.com Australia

Feb 25, 2026
pulisher
Feb 25, 2026

IQVIA to acquire drug discovery assets from Charles River Labs - Investing.com

Feb 25, 2026

Charles River Laboratories International Inc (CRL) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
diagnostics_research DGX
$200.56
price down icon 0.17%
diagnostics_research LH
$270.42
price up icon 0.64%
diagnostics_research MTD
$1,228.93
price down icon 0.23%
$196.61
price down icon 1.18%
diagnostics_research IQV
$171.58
price up icon 0.38%
diagnostics_research WAT
$297.54
price down icon 0.70%
大文字化:     |  ボリューム (24 時間):